Accounting for up to 80% of all dementia cases, Alzheimer’s disease (AD) currently affects over 50 million people across the globe. With 10 million new cases of dementia diagnosed each year, this number is expected to increase with a steadily rising aging population leading experts to forecast there will be nearly 152 million dementia patients by the year 2050. The significant caregiving and economic burden of this condition necessitate innovations in therapeutics that will enable clinicians to implement effective prevention and treatment methods. Today, the socio-economical cost of dementia is estimated at $1 trillion – and this is expected to double by the end of the decade if rates do not slow down.

Continue reading →